Risk prediction and finding new independent prognostic factors

Journal of Hypertension

Volumn 24, Issue 4, 2006, Pages 643-645

  D'Agostino, Ralph B ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; C REACTIVE PROTEIN; LOSARTAN;

ANTIHYPERTENSIVE THERAPY; GENDER; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SMOKING;

EID: 33645520190     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000217845.57466.cc     Document Type: Note

References (17)

1. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation 1991; 83:356-362.
2. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121:293-298.
3. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
4. D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, Hartz SC. Primary and subsequent coronary risk appraisal: new results from the Framingham Study. Am Heart J 2000; 139:272-281.
5. D'Agostino RB, Grundy S, Sullivan LM, Wilson PWF. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286:180-187.
6. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. Stroke 1994; 25:40-43.
7. Assman G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) Study. Circulation 2002; 105:310-315.
8. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al., for the SCORE project group. Estimation of 10-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003.
9. Wilson PWF. Metabolic risk factors for coronary heart disease: current and future prospects. Curr Opin Cardiol 1999; 14:176-185.
10. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004; 291:210-215.
11. Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001; 104:1863-1867.
12. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565.
13. Wilson PWF, Nam B-H, Pencina M, D'Agostino RB, Benjamin E, O'Donnell C. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005; 165:2473-2478.
14. D'Agostino RB, Nam B-H. Evaluation of the performance of survival analysis models: discrimination and calibration methods. In: Balakrishnan N, Rao CR, editors. Handbook of statistics, vol. 23, survival methods. Amsterdam: Elsevier; 2004, pp. 1-25.
15. Pencina M, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004; 23:2109-2123.
16. Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlof B, Devereux RB, et al. Reduction in albuminuria and in electocardiographic left ventricular hypertrophy independently improve prognosis in hypertension. The LIFE study. J Hypertens 2006; 24:775-781.
17. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004; 15:882-890.